Cytopenia clinical trials
The registry lists 81 studies for Cytopenia across more than 10 countries. 25 are recruiting or about to start. 25 of them are mainly about Cytopenia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its 13 narrower conditions too, such as Purpura, Thrombocytopenic, Idiopathic: 1,658 studies, 399 open.
Get an email when these change. Save the Cytopenia studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Ortho Pharmaceuticals (6) · Sandoz (6) · Amgen (4) · Bellicum Pharmaceuticals (3) · Takeda (3) · National Heart, Lung, and Blood Institute (NHLBI) (3) · National Cancer Institute (NCI) (2) · Memorial Sloan Kettering Cancer Center (2)
What is being tested here
Drugs under test in Cytopenia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 6
- Dec 2026HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy · Children's Hospital Medical Center, Cincinnati
- Dec 2026Early Intervention in High Risk CCUS · Lachelle D. Weeks, MD, PhD
- Jan 2027Feasibility and Safety of Exercise in Patients With Low-risk Myeloid Cancers and Precursor Conditions · Rigshospitalet, Denmark
- Aug 2027Autologous Hematopoietic Stem Cell Infusion for Prolonged Cytopenia After CAR-T Cell Therapy · Institute of Hematology & Blood Diseases Hospital, China
- Aug 2027Danazol for Treatment of Cytopenias in Patients With Cirrhosis · University of Southern California
- Sep 2027Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in the Treatment of Long-Term Cytopenia After CAR-T Therapy · Institute of Hematology & Blood Diseases Hospital, China
Who these studies take
Of the 20 Cytopenia studies recruiting now, 17 (85%) set no upper age limit and 1 (5%) stop at 75 or younger. 3 (15%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (15%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (15%) | 3 (15%) |
| 18 | 20 (100%) | 20 (100%) |
| 30 | 19 (95%) | 19 (95%) |
| 40 | 19 (95%) | 19 (95%) |
| 50 | 19 (95%) | 19 (95%) |
| 65 | 19 (95%) | 19 (95%) |
| 75 | 19 (95%) | 19 (95%) |
| 85 | 19 (95%) | 19 (95%) |
Across all 81 studies, recruiting or not: 31% stop at 75 or younger and 21% at 65; 27% take children; 1% are for women only and 4% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Newly registered1
Studies
Recruiting first, then most recently updated. Showing 50 of 81. Browse all 81 → or search them.
- Screening for Hematology Branch ProtocolsEnrolling by invitationNCT000016201 country
- Modulation of Stem Cell Differentiation in Individuals With High Risk Clonal HaematopoiesisNot yet recruitingNCT07435636Phase 21 country
- A Study of Mezagitamab in Adults With Chronic Primary Immune ThrombocytopeniaRecruitingNCT06722235Phase 318 countries
- A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune ThrombocytopeniaRecruitingNCT06948318Phase 315 countries
- Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell CytopeniasNot yet recruitingNCT07895017Phase 21 country
- Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in the Treatment of Long-Term Cytopenia After CAR-T TherapyRecruitingNCT07212335Early Phase 11 country
- A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)RecruitingNCT04419649Phase 28 countries
- Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDSRecruitingNCT053507481 country
- Long-Term Follow-Up Study of GamgertamigNot yet recruitingNCT07847892
- CHIP/CCUS Natural History ProtocolRecruitingNCT041024231 country
- Autoimmune Cytopenia Elimination by Chimeric Antigen Receptor T-cell TherapyNot yet recruitingNCT07790575Phase 11 country
- Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized TrialRecruitingNCT06240754Phase 21 country
- A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged CytopeniaRecruitingNCT06285825Phase 21 country
- Early Intervention in High Risk CCUSRecruitingNCT06802146Early Phase 11 country
- Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in Cytopenia PatientsRecruitingNCT070810871 country
- Pre-myeloid Cancer and Bone Marrow Failure Clinic StudyRecruitingNCT02958462Not applicable1 country
- Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT StudyRecruitingNCT05641831Phase 21 country
- Epidemiological, Clinical and Biological Characteristics of Human Anaplasmosis Cases in AlsaceRecruitingNCT073124741 country
- A Study of Emapalumab for Pediatric Aplastic AnemiaRecruitingNCT06430788Phase 21 country
- HSCT for Patients With Fanconi Anemia Using Risk-Adjusted ChemotherapyRecruitingNCT02143830Phase 21 country
- Feasibility and Safety of Exercise in Patients With Low-risk Myeloid Cancers and Precursor ConditionsRecruitingNCT06773871Not applicable1 country
- Autologous Hematopoietic Stem Cell Infusion for Prolonged Cytopenia After CAR-T Cell TherapyRecruitingNCT07127289Phase 21 country
- Danazol for Treatment of Cytopenias in Patients With CirrhosisRecruitingNCT04873102Phase 21 country
- Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDSRecruitingNCT04741945Phase 21 country
- Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow MicroenvironmentRecruitingNCT064391731 country
- Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 DepletionActive, not recruitingNCT05236764Not applicable1 country
- Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUSActive, not recruitingNCT033293651 country
- Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1Active, not recruitingNCT05030441Phase 21 country
- National Prospective Cohort for Monitoring Children With Severe Autoimmune Cytopenia.CompletedNCT04070612
- 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and CytopeniaWithdrawnNCT07025512Phase 2
- The National Myelodysplastic Syndromes (MDS) StudyCompletedNCT027753832 countries
- A Study of Enasidenib in People With Clonal Cytopenia of Undetermined SignificanceCompletedNCT05102370Phase 11 country
- BMS-986253 in Myelodysplastic SyndromesTerminatedNCT05148234Phase 1/21 country
- JSP191 (briquilimab) in Subjects with LR-MDSTerminatedNCT05903274Phase 11 country
- Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid MalignanciesActive, not recruitingNCT03682029Not applicable2 countries
- Autoimmune Cytopenias as a Sign of Primary Immunodeficiency.Active, not recruitingNCT06276036Not applicable3 countries
- Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell TransplantTerminatedNCT02065869Phase 1/22 countries
- Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical StudyTerminatedNCT03733249Phase 1/21 country
- Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell TransplantActive, not recruitingNCT03301168Phase 1/21 country
- Sertraline in Treatment of Low-Risk Myelodysplastic SyndromeTerminatedNCT02452983Phase 11 country
- Cytopenias in Hospitalized Patients of Corona Virus Infection(COVID-19) During First and Other WavesCompletedNCT052588121 country
- Granulocyte-Macrophage Colony-Stimulating Factor and Zidovudine: A Phase I Study of Concurrent Administration in Patients With AIDS and Severe ARCCompletedNCT00000711Phase 11 country
- Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell TransplantNo longer availableNCT012000171 country
- Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or DecitabineCompletedNCT01928537Phase 38 countries
- Umbilical Cord Blood Treatment for Refractory Immune CytopeniaStatus unknownNCT04420494Not applicable1 country
- Sirolimus for Autoimmune Disease of Blood CellsCompletedNCT00392951Phase 1/21 country
- Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.CompletedNCT01868477Phase 210 countries
- Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating AgentsCompletedNCT00321711Phase 2
- Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic CancerTerminatedNCT00295880Phase 1/2
- Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal CancerCompletedNCT00771810Phase 21 country